Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165539 | 0.79 | HTR2A (0.42) | NR3C2SLC6A2SLC6A4 | |
| SCHEMBL16234664 | 0.71 | NR3C2 (0.36) | KDM4ENR3C2SLC6A2SLC6A4 | |
| SCHEMBL10165371 | 0.70 | HTR2A (0.42) | SLC6A2SLC6A4 | |
| SCHEMBL10165547 | 0.68 | KCNQ3 (0.33) | — | |
| SCHEMBL10165368 | 0.67 | KMO (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12180506 | 0.66 | EZH2 (0.37) | KDM4E | |
| SCHEMBL31607587 | 0.66 | RHEB (0.38) | KDM4ESLC6A4 | |
| SCHEMBL10165378 | 0.64 | SLC6A2 (0.41) | KDM4ESLC6A2SLC6A4 | |
| SCHEMBL10165548 | 0.63 | HTR2A (0.41) | KDM4ENR3C2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30858469 | 0.62 | HTR2C (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | KDM4E 2356/4885NR3C2 3904/4885SLC6A2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.